As of 2025-12-14, the EV/EBITDA ratio of Cue Biopharma Inc (CUE) is -0.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CUE's latest enterprise value is 28.30 mil USD. CUE's TTM EBITDA according to its financial statements is -37.73 mil USD. Dividing these 2 quantities gives us the above CUE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.0x | 14.9x |
| Forward P/E multiples | 18.9x - 34.2x | 21.4x |
| Fair Price | (8.94) - (7.05) | (8.57) |
| Upside | -1934.9% - -1547.4% | -1859.2% |
| Date | EV/EBITDA |
| 2025-12-11 | -0.76 |
| 2025-12-10 | -0.73 |
| 2025-12-09 | -0.77 |
| 2025-12-08 | -0.84 |
| 2025-12-05 | -0.88 |
| 2025-12-04 | -0.89 |
| 2025-12-03 | -0.90 |
| 2025-12-02 | -0.93 |
| 2025-12-01 | -0.98 |
| 2025-11-28 | -1.05 |
| 2025-11-26 | -1.04 |
| 2025-11-25 | -1.00 |
| 2025-11-24 | -0.97 |
| 2025-11-21 | -0.98 |
| 2025-11-20 | -0.86 |
| 2025-11-19 | -0.94 |
| 2025-11-18 | -0.94 |
| 2025-11-17 | -0.93 |
| 2025-11-14 | -1.05 |
| 2025-11-13 | -1.03 |
| 2025-11-12 | -1.13 |
| 2025-11-11 | -1.16 |
| 2025-11-10 | -1.15 |
| 2025-11-07 | -1.20 |
| 2025-11-06 | -1.23 |
| 2025-11-05 | -1.26 |
| 2025-11-04 | -1.24 |
| 2025-11-03 | -1.23 |
| 2025-10-31 | -1.34 |
| 2025-10-30 | -1.19 |
| 2025-10-29 | -1.17 |
| 2025-10-28 | -1.27 |
| 2025-10-27 | -1.34 |
| 2025-10-24 | -1.37 |
| 2025-10-23 | -1.36 |
| 2025-10-22 | -1.33 |
| 2025-10-21 | -1.46 |
| 2025-10-20 | -1.45 |
| 2025-10-17 | -1.40 |
| 2025-10-16 | -1.38 |
| 2025-10-15 | -1.37 |
| 2025-10-14 | -1.40 |
| 2025-10-13 | -1.43 |
| 2025-10-10 | -1.39 |
| 2025-10-09 | -1.67 |
| 2025-10-08 | -1.52 |
| 2025-10-07 | -1.30 |
| 2025-10-06 | -1.25 |
| 2025-10-03 | -1.26 |
| 2025-10-02 | -1.23 |